Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10515	Companies
221776	Keywords
150984	Articles
117325	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 06/06/2024 at 13:00, 1 year 11 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Moderna's mRNA-3705 selected for FDA's START pilot program to address rare diseases. The investigational mRNA therapeutic aims to treat methylmalonic acidemia due to MUT deficiency with innovative mRNA platform

Moderna Rare Diseases MMA MRNA-3705 START Pilot Program
PRESS RELEASE

published on 06/03/2024 at 14:00, 2 years ago

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage II
BRIEF

published on 05/31/2024 at 17:03, 2 years ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA

FDA Approval Moderna Vaccine RSV MRESVIA
PRESS RELEASE

published on 05/31/2024 at 16:58, 2 years ago

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
Moderna gains FDA approval for mRESVIA, a single-dose pre-filled syringe RSV vaccine for adults 60+ to prevent lower respiratory tract disease. Second mRNA product and breakthrough therapy designation

FDA Approval Moderna RSV Vaccine MRNA MRESVIA
BRIEF

published on 05/22/2024 at 13:05, 2 years ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Clinical Trials Immunotherapy Moderna ASCO 2024 MRNA-4157
PRESS RELEASE

published on 05/22/2024 at 13:00, 2 years ago

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna to host an investor event via webcast on June 3 at 6:15 PM CDT. Abstracts on mRNA-4157 for ASCO Annual Meeting. Details on mRNA-4157 (V940) therapy development

Webcast Moderna Investor Event MRNA-4157 Neoantigen Therapy
BRIEF

published on 05/13/2024 at 13:05, 2 years ago

Moderna Announces Participation in Key Investor Conferences

Investor Conferences Healthcare Financial Markets Moderna Webcasts
PRESS RELEASE

published on 05/13/2024 at 13:00, 2 years ago

Moderna to Present at Upcoming Conferences in May/June 2024
Moderna, Inc. to participate in upcoming investor conferences, showcasing its leadership in mRNA medicine and innovative approach to disease treatment. Live webcasts available

Investor Conferences Moderna Inc. MRNA Medicine Webcasts Disease Treatment
BRIEF

published on 05/02/2024 at 12:35, 2 years 1 month ago

Moderna Reports Q1 2024 Financial Performance and Strategic Progress

Financial Results MRNA Technology Moderna RSV Vaccine Vaccine Development
PRESS RELEASE

published on 05/02/2024 at 12:30, 2 years 1 month ago

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q1 revenues of $167 million, GAAP net loss of $1.2 billion, and diluted EPS of $(3.07). Company prepares for RSV vaccine and Spikevax® 2024-2025 formula launches, with expected product sales of $4 billion in 2024

Moderna Inc. Net Loss RSV Vaccine Q1 Revenues Spikevax 2024-2025 Formula

Accesswire

Published on 06/04/2026 at 18:25, 2 hours 12 minutes ago

Touchstone Exploration Inc. Proposed Fundraise of US$10 Million to US$15 Million
Published on 06/04/2026 at 14:45, 5 hours 52 minutes ago

Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 2026
Published on 06/04/2026 at 14:30, 6 hours 7 minutes ago

Predictiv AI's Shift Technologies Secures Multi-Phase Commercial Contract to Digitize and Scale Middle-Mile and Last-Mile Logistics for Prompt Xpress
Published on 06/04/2026 at 14:00, 6 hours 37 minutes ago

Horizon Aircraft Appoints Richard Alexander as Chief Engineer of Certified Programs
Published on 06/04/2026 at 14:00, 6 hours 37 minutes ago

GameSquare Issues Shareholder Letter Highlighting Strong Second Quarter and Year-to-Date Momentum

View all ACCESSWIRE

EQS Group

Published on 06/04/2026 at 20:00, 37 minutes ago

Notes Reduction - Results of Consent Solicitation
Published on 06/04/2026 at 19:27, 1 hour 10 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/04/2026 at 18:30, 2 hours 6 minutes ago

FROM DUPLANTIS TO PALTRINIERI, FAIR PLAY MENARINI KICKS OFF ITS 30TH EDITION
Published on 06/04/2026 at 17:57, 2 hours 39 minutes ago

EQS-Adhoc: Viscom SE raises its forecast for incoming orders in the 2026 financial year following a major contract
Published on 06/04/2026 at 17:50, 2 hours 46 minutes ago

Monport Laser Showcases Engraving Opportunities in Germany Ahead of World Cup 2026

Les Echos

Published on 06/04/2026 at 20:00, 37 minutes ago

Schneider Electric announces the reference share price the initial conversion/exchange ratio of its €850 million new bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2034 and the results of the repurchase of the OC
Published on 06/04/2026 at 18:23, 2 hours 14 minutes ago

Shareholders’ Meeting and board of directors’ meeting held on June 4, 2026
Published on 06/04/2026 at 18:00, 2 hours 37 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of May 29, 2026
Published on 06/04/2026 at 17:45, 2 hours 52 minutes ago

Declaration of voting rights at the end of May 2026
Published on 06/04/2026 at 17:45, 2 hours 52 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE